Genomics is central to the precision oncology cascade. After tissue or blood is subjected to next-generation sequencing (NGS) and bioinformatics analysis, the alterations detected must be annotated and interpreted within the context of the individual patient.
This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.
Samantha Hasenleithner of the Medical University of Graz will discuss the approach, which reflects a true clinical scenario in which both plasma and tissue analytes help inform treatment decisions. Nevertheless, this workflow poses challenges for clinicians in selecting the appropriate treatment.
Clinical decision support may help streamline these variant interpretation and treatment matching workflows, and Dr. Hasenleithner will discuss an evaluation of three such tools and her team’s experience with the Navify Mutation Profiler*.
*For Research Use Only. Not for use in diagnostic procedures in the US.
